Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E Mendes

Showing results (141-150 of 473) with videos related to

Pageof 48
Sort By:
Antibiotics (Basel, Switzerland)|June 27, 2024
Activity of Aztreonam/Avibactam and Recently Approved β-Lactamase Inhibitor Combinations against Enterobacterales and <i>Pseudomonas aeruginosa</i> from Intensive Care Unit and Non-Intensive Care Unit PatientsHelio S Sader, Rodrigo E Mendes, John H Kimbrough, et al.
The Journal of Antimicrobial Chemotherapy|February 17, 2009
TR-700 in vitro activity against and resistance mutation frequencies among Gram-positive pathogensRonald N Jones, Gary J Moet, Helio S Sader, et al.
Diagnostic Microbiology and Infectious Disease|March 24, 2018
Oritavancin in vitro activity against gram-positive organisms from European and United States medical centers: results from the SENTRY Antimicrobial Surveillance Program for 2010-2014M A Pfaller, H S Sader, R K Flamm, et al.
International Journal of Antimicrobial Agents|March 7, 2018
In vitro activity of meropenem/vaborbactam and characterisation of carbapenem resistance mechanisms among carbapenem-resistant Enterobacteriaceae from the 2015 meropenem/vaborbactam surveillance programmeMichael A Pfaller, Michael D Huband, Rodrigo E Mendes, et al.
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|June 25, 2004
Antimicrobial susceptibility of Streptococcus pneumoniae in Latin America: results from five years of the SENTRY Antimicrobial Surveillance ProgramM Castanheira, A C Gales, R E Mendes, et al.
Phytopathology|October 24, 2008
Conidia as a Substrate for Internal Transcribed Spacer-Based PCR Identification of Members of the Leptosphaeria maculans Species ComplexM H Balesdent, M Jedryczka, L Jain, et al.
The Brazilian Journal of Infectious Diseases : an Official Publication of the Brazilian Society of Infectious Diseases|November 4, 2000
In vitro antimicrobial activity of piperacillin/tazobactam in comparison with other broad-spectrum beta-lactamsR K Roland, R E Mendes, S Silbert, et al.
Journal of Global Antimicrobial Resistance|July 24, 2017
Activity of dalbavancin tested against Gram-positive clinical isolates causing skin and skin-structure infections in paediatric patients from US hospitals (2014-2015)Michael A Pfaller, Rodrigo E Mendes, Helio S Sader, et al.
Open Forum Infectious Diseases|March 22, 2019
Temporal and Geographic Variation in Antimicrobial Susceptibility and Resistance Patterns of Enterococci: Results From the SENTRY Antimicrobial Surveillance Program, 1997-2016Michael A Pfaller, Martin Cormican, Robert K Flamm, et al.
Antimicrobial Agents and Chemotherapy|February 11, 2015
Use of in vitro vancomycin testing results to predict susceptibility to oritavancin, a new long-acting lipoglycopeptideRonald N Jones, John D Turnidge, Greg Moeck, et al.
Pageof 48

Showing results (141-150 of 473) with videos related to

Sort By:
Pageof 48
Antibiotics (Basel, Switzerland)|June 27, 2024
Activity of Aztreonam/Avibactam and Recently Approved β-Lactamase Inhibitor Combinations against Enterobacterales and <i>Pseudomonas aeruginosa</i> from Intensive Care Unit and Non-Intensive Care Unit PatientsHelio S Sader, Rodrigo E Mendes, John H Kimbrough, et al.
The Journal of Antimicrobial Chemotherapy|February 17, 2009
TR-700 in vitro activity against and resistance mutation frequencies among Gram-positive pathogensRonald N Jones, Gary J Moet, Helio S Sader, et al.
Diagnostic Microbiology and Infectious Disease|March 24, 2018
Oritavancin in vitro activity against gram-positive organisms from European and United States medical centers: results from the SENTRY Antimicrobial Surveillance Program for 2010-2014M A Pfaller, H S Sader, R K Flamm, et al.
International Journal of Antimicrobial Agents|March 7, 2018
In vitro activity of meropenem/vaborbactam and characterisation of carbapenem resistance mechanisms among carbapenem-resistant Enterobacteriaceae from the 2015 meropenem/vaborbactam surveillance programmeMichael A Pfaller, Michael D Huband, Rodrigo E Mendes, et al.
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|June 25, 2004
Antimicrobial susceptibility of Streptococcus pneumoniae in Latin America: results from five years of the SENTRY Antimicrobial Surveillance ProgramM Castanheira, A C Gales, R E Mendes, et al.
Phytopathology|October 24, 2008
Conidia as a Substrate for Internal Transcribed Spacer-Based PCR Identification of Members of the Leptosphaeria maculans Species ComplexM H Balesdent, M Jedryczka, L Jain, et al.
The Brazilian Journal of Infectious Diseases : an Official Publication of the Brazilian Society of Infectious Diseases|November 4, 2000
In vitro antimicrobial activity of piperacillin/tazobactam in comparison with other broad-spectrum beta-lactamsR K Roland, R E Mendes, S Silbert, et al.
Journal of Global Antimicrobial Resistance|July 24, 2017
Activity of dalbavancin tested against Gram-positive clinical isolates causing skin and skin-structure infections in paediatric patients from US hospitals (2014-2015)Michael A Pfaller, Rodrigo E Mendes, Helio S Sader, et al.
Open Forum Infectious Diseases|March 22, 2019
Temporal and Geographic Variation in Antimicrobial Susceptibility and Resistance Patterns of Enterococci: Results From the SENTRY Antimicrobial Surveillance Program, 1997-2016Michael A Pfaller, Martin Cormican, Robert K Flamm, et al.
Antimicrobial Agents and Chemotherapy|February 11, 2015
Use of in vitro vancomycin testing results to predict susceptibility to oritavancin, a new long-acting lipoglycopeptideRonald N Jones, John D Turnidge, Greg Moeck, et al.
Pageof 48